26 M. R. Grever & P. L. Zinzani
6. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up 15. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-
of patients with hairy cell leukemia after treatment with up of remission duration, mortality, and second malignancies
2
0
-deoxycoformycin. Blood 1994;84:4061–4063. in hairy cell leukemia patients treated with pentostatin. Blood
7. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: 2000;96:2981–2986.
induction of complete remission with pentostatin (2
0
-deoxy- 16. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of
coformycin). J Clin Oncol 1984;2:1336–1342. front-line treatment of hairy cell leukemia with 2-chlorodeox-
8. Maloisel F, Benboubker L, Gardembas M, et al. Long-term yadenosine. Haematologica 2004;89:309–313.
outcome with pentostatin treatment in hairy cell leukemia 17. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up
patients. A French retrospective study of 238 patients. of patients with hairy cell leukemia after treatment with
Leukemia 2003;17:45–51. cladribine. J Clin Oncol 2003;21:891–896.
9. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in 18. Else M, Dearden CE, Matutes E, et al. Long-term follow-up
hairy-cell leukemia induced by a single infusion of 2-chlor- of 233 patients with hairy cell leukaemia, treated initially with
odeoxyadenosine. N Engl J Med 1990;322:1117–1121. pentostatin or cladribine, at a median of 16 years from
10. Saven A, Burian C, Koziol JA, et al. Long-term follow-up of diagnosis. Br J Haematol 2009;145:733–740.
patients with hairy cell leukemia after cladribine treatment. 19. Golomb HM. Hairy cell leukemia: treatment successes in the
Blood 1998;92:1918–1926. past 25 years. J Clin Oncol 2008;26:2607–2609.
11. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of 20. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a
hairy cell leukemia after 2-chlorodeoxyadenosine: long-term weekly versus daily schedule for untreated active hairy cell
follow-up of the Northwestern University experience. Blood leukemia: final report from the Polish Adult Leukemia Group
1996;88:1954–1959. (PALG) of a prospective, randomized, multicenter trial. Blood
12. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of 2007;109:3672–3675.
hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): 21. Ravandi F, O’Brien S. Infections associated with purine
long-term follow-up of the Northwestern University experi- analogs and monoclonal antibodies. Blood Rev 2005;19:253–
ence. Blood 2005;106:241–246. 273.
13. Dearden CE, Matutes E, Hilditch BL, et al. Long-term 22. Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer
follow-up of patients with hairy cell leukaemia after treatment incidence and cause-specific mortality among 3104 patients
with pentostatin or cladribine. Br J Haematol 1999;106:515– with hairy cell leukemia: a population-based study. J Natl
519. Cancer Inst 2007;99:215–222.
14. Johnston JB, Eisenhauer E, Wainman N, et al. Long-term 23. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann
outcome following treatment of hairy cell leukemia with V. An update: 12-year follow-up of patients with hairy cell
pentostatin (Nipent): a National Cancer Institute of Canada leukemia following treatment with 2-chlorodeoxyadenosine.
study. Semin Oncol 2000;27:32–36. Leukemia 2004;18:1476–1481.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46